<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-BVTDVOAH/9270071e-fba6-405d-b48c-94bc014f037a/HTML"><dcterms:extent>35 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-BVTDVOAH/1677c59f-1408-4cc1-ac39-d97eb8aa10f5/PDF"><dcterms:extent>251 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-BVTDVOAH/a6d04c22-72c9-44b9-beb4-2a1e9e253605/TEXT"><dcterms:extent>31 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-BVTDVOAH"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2013</dcterms:issued><dc:creator>Frlan, Rok</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">letnik:64</dc:format><dc:format xml:lang="sl">str. 218-226</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:3501169</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-BVTDVOAH</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">Helicobacter pylori</dc:subject><dc:subject xml:lang="sl">peptična razjeda</dc:subject><dc:subject xml:lang="sl">sečni kamni</dc:subject><dc:subject xml:lang="sl">ureaze</dc:subject><dc:subject xml:lang="sl">zaviralci</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Zaviralci ureaze| Urease inhibitors|</dc:title><dc:description xml:lang="sl">Urease is an enzyme that catalyzes the hydrolysis of urea to ammonia and carbamate. Ureolytic activity of human pathogens, such as Helicobacter pylori,Proteus spp. and others is thought to be a causative factor of many clinical conditions, such as peptic ulcer and urinary infection stones. The most efficient therapy which is quite successful at the moment is complete eradication of bacteria and treatment of disease symptoms. Because of the increasing resistance to antibacterial agents the design of new treatment routes is becoming a new focal point to control these diseases in the future. One of perspective targets in the design of novel inhibitors and vaccines is urease. Many inhibitors have been developed so far, however only one compound,acetohydroxamic acid, has been used clinically for the treatment of urinary tract infections</dc:description><dc:description xml:lang="sl">Ureaza je encim, ki katalizira hidrolizo sečnine do amoniaka in karbamske kisline. Ta encim je tudi eden glavnih vzrokov za razvoj mnogih bolezni, ki nastanejo zaradi okužb z urolitičnimi mikroorganizmi. Med temi sta najbolj poznani peptična razjeda, ki jo povzroča Helicobacter pylori, in sečni kamni, ki jih povzročajo Proteus spp. ter nekatere druge ureolitične bakterije. Izkoreninjenje bakterij in zdravljenje posledic okužbe je najučinkovitejši način terapije. Ta je zaenkrat relativno uspešna, vendar je ob naglem povečevanju rezistence na protibakterijske učinkovine načrtovanje in razvoj novih načinov zdravljenja pomemben ukrep za učinkovit nadzor nad omenjenimi okužbami. Ena od zelo perspektivnih tarč pri razvoju novih zaviralcev in cepiv so prav ureaze. Razvitih je bilo mnogo selektivnih zaviralcev ureaze, od katerih je najbolj poznana acetohidroksamska kislina, ki je tudi edina z dovoljenjem FDA za uporabo pri okužbah urinarnega trakta</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-BVTDVOAH"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-BVTDVOAH" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-BVTDVOAH/1677c59f-1408-4cc1-ac39-d97eb8aa10f5/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-BVTDVOAH/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-BVTDVOAH" /></ore:Aggregation></rdf:RDF>